TürkiyeSGK and reimbursement
Reimbursement criteria for nusinersen and risdiplam in SMA revised
A statement by a ministry, institution or international organisation, or a change in regulations. It is not evidence about how well a treatment works.
The criteria for the use and reimbursement of nusinersen and risdiplam in SMA treatment have been revised. The revision came through an amendment to the Sağlık Uygulama Tebliği (SUT, Health Implementation Communiqué). The amendment was published in the Resmî Gazete (Official Gazette) on June 29, 2026. Some of the changes took effect five days after publication.
What does it mean for patients and families?
Have the medical report and application requirements changed? People with SMA should ask the SMA center that follows them.
Source
Gazete Oksijen: Resmi Gazete'de yayımlandı: İlaç, tedavi ve geri ödeme kuralları değişti
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Spinal muscular atrophy (SMA)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.